The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
 
Oliver Klein
Honoraria - Bristol-Myers Squibb; MSD Australia
Research Funding - Bristol-Myers Squibb (Inst)
 
Damien Kee
No Relationships to Disclose
 
Ben Markman
Consulting or Advisory Role - Novartis
 
Rachael Chang Lee
No Relationships to Disclose
 
Michael Michael
Consulting or Advisory Role - Ipsen; Merck
 
Linda R. Mileshkin
Travel, Accommodations, Expenses - BeiGene; Roche; Roche
 
Clare L. Scott
Research Funding - Clovis Oncology; Eisai; Roche/Genentech; Sierra Oncology
Patents, Royalties, Other Intellectual Property - Royalty agreement for venetoclax (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca
Other Relationship - Clovis Oncology; Merck Serono; Takeda
 
Richelle Linklater
No Relationships to Disclose
 
Sid Menon
No Relationships to Disclose
 
Niall C. Tebbutt
Honoraria - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer; Roche
 
Jodie Palmer
No Relationships to Disclose
 
Andreas Behren
No Relationships to Disclose
 
Jonathan S. Cebon
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Amgen (Inst); Bionomics; Bionomics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis; Novartis (Inst)
Research Funding - CSL Behring (Inst); GlaxoSmithKline (Inst)
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Expert Testimony - Bristol-Myers Squibb